Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT06694454 · SUSPENDED

Trial details

NCT number: NCT06694454
Sponsor: National Cancer Institute (NCI)
Status: SUSPENDED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell Lung Non-Small Cell Lung Carcinoma Non Small Cell Lung Cancer Non Small Cell Lung Carcinoma

Start date: 2026-08-23
Primary completion: 2031-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.